Enhanced recovery of erythroid cells in ROCK1^−/− mice in response to 5-FU. (A) Whole BM cells from WT and ROCK1^−/− mice were harvested at 0, 3, 6, and 21 days after 5-FU injection. The quadrant in each dot blot indicates the percentage of Ter119-positive cells in WT and ROCK1^−/− mice at 0, 3, 6, and 21 days after 5-FU treatment. (B) Line chart represents the mean ± SEM value of percent of Ter119-positive cells in WT and ROCK1^−/− BM at indicated time points after 5-FU treatment (n = 8 mice per genotype for the 3 day time point; 3 mice per genotype for the 6 day and 21 day time point, *P < .05). (C) The percentage of CD71/Ter119 double-positive cells in the spleen of representative WT and ROCK1^−/− mice is indicated in the top-right quadrant of each dot blot in response to 5-FU at 21 days after 5-FU treatment. (D) Line chart represents the mean ± SEM value of percentage of CD71/Ter119 double-positive cells in spleen of WT and ROCK1^−/− mice at 0, 3, 6, 9, and 21 days after 5-FU treatment (n = 8 mice per genotype for the 3 day time point; 3 mice per genotype for the 6 day, 9 day, and 21 day time points, *P < .05). (E) Whole BM cells from WT and ROCK1^−/− mice were harvested 6 days after 5-FU injection, stained with anti-Ter119 antibody followed by annexin V and 7-AAD staining. Left panel shows gated histogram representing Ter119-positive cells in WT and ROCK1^−/− mice at 6 days after 5-FU treatment. Dot blot in the right panel represents the percentage of annexin V or 7-AAD or double-positive Ter119-positive cells in both genotypes after 5-FU treatment. (F) Bar graph represents mean ± SEM of annexin V–positive cells in the BM of WT and ROCK1^−/− mice after 5-FU treatment. (n = 3 mice per genotype, *P < .05).